Medtronic Brain Modulation

Patients' symptoms don't stay the same - neither should their therapy. BrainSense™ technology and advanced programming capabilities let you personalize DBS therapy to your patients’ evolving needs over time.† https://lnkd.in/g58awZJN Product usage represented may not be approved or cleared in all markets. †The sensing feature of the Percept™ PC system and Percept™ RC system is intended for use in patients receiving DBS where chronically recorded bioelectric data may provide useful, objective information regarding patient clinical status. The majority of patients with Parkinson’s disease have an identifiable signal. Signal may not be present or measurable in patients treated for essential tremor, dystonia, epilepsy, or obsessive-compulsive disorder. Humanitarian device: The effectiveness of these devices for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated.

In honor of Parkinson’s Awareness Month, we’d like to recognize all the healthcare professionals that work tirelessly to advance the treatment of Parkinson’s disease. Casey Halpern, neurosurgeon, with Penn Medicine performed the first U.S. patient implant of our new Percept™ RC neurostimulator with exclusive BrainSense™ technology. Watch as he shares his experience and why he believes sensing is the future of DBS therapy. #parkinsonsawarenessmonth #takeyournextstep #medtronicdbs

New ADAPT-PD clinical trial data was presented at #AAN2024. Here is the abstract in case you missed it! https://lnkd.in/gAxNkrDQ #MedtronicDBS Adaptive DBS (aDBS) is investigational and is not approved by the Food and Drug Administration (FDA) for commercialization in the United States (US). In the US, the safety and effectiveness of aDBS has not been established.

Navy vet Andy, battled daily with Parkinson's. Medtronic DBS helped him regain independence. Watch his story #takeyournextstep and share resources https://bit.ly/3VJ2Gpn

While you're in the Mile High City, come say hello to the Percept™ family, the most advanced deep brain stimulation (DBS) technology now available in different models to meet unique patient needs. #MedtronicDBS https://bit.ly/3xpb7vR

New ADAPT-PD clinical trial data will be presented by Dr. Helen Bronte-Stewart at #AAN2024. Attend the oral presentation on Sunday, April 14 to learn more. Visit the AAN site for additional details: https://lnkd.in/gAxNkrDQ Adaptive DBS (aDBS) is investigational and is not approved by the Food and Drug Administration (FDA) for commercialization in the United States (U.S.). In the U.S., the safety and effectiveness of aDBS has not been established. 

#ParkinsonsAwarenessMonth

Join us at #AAN2024 to discover the latest in deep brain stimulation (DBS) therapy. We can’t wait to show you what’s new with #MedtronicDBS. https://bit.ly/3xpb7vR

March is National Essential Tremor Awareness Month. Help patients know the signs of essential tremor so they know what questions to ask their healthcare providers. https://lnkd.in/etwcRUKj

Calling all clinicians who are experienced with DBS patient management and the general concepts of programming. Be sure to attend this course that includes case-based discussion around advanced issues to help with achieving therapy goals. Topics covered will include an overview of Medtronic’s SenSight™ directional lead system, the Percept™ PC and Percept™ RC neurostimulators as well as areas related to longevity, troubleshooting, and other advanced management techniques. BrainSense™ technology† case studies are included and discussed as well as the workflow. #MedtronicDBS †The sensing feature of the Percept™ PC and Percept™ RC systems are intended for use in patients receiving DBS where chronically-recorded bioelectric data may provide useful, objective information regarding patient clinical status. The majority of patients with Parkinson’s disease have an identifiable signal. Signal may not be present or measurable in patients treated for essential tremor, dystonia**, epilepsy or obsessive-compulsive disorder**. **Humanitarian Device: The effectiveness of these devices for the treatment of dystonia and obsessive-compulsive disorder has not been demonstrated. See important risk information here: https://bit.ly/4cxIJHY ©2024 Medtronic. Medtronic, Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. All other brands are trademarks of a Medtronic company.